ML133 HCl: Selective Kir2.1 Channel Blocker for Pulmonary and Cardiovascular Ion Channel Research

Executive Summary: ML133 HCl is a potent and selective potassium channel inhibitor that targets Kir2.1 channels with nanomolar to micromolar efficacy depending on pH (IC₅₀ of 1.8 μM at pH 7.4; 290 nM at pH 8.5) (APExBIO). The compound exhibits negligible inhibition of Kir1.1 and weak activity against Kir4.1/Kir7.1, ensuring high selectivity (Cao et al., 2022). ML133 HCl is widely used in research on pulmonary artery smooth muscle cell (PASMC) proliferation and migration, with direct relevance to cardiovascular disease models (CPI-613 article). Its defined chemical properties and solubility profile facilitate integration into standard laboratory workflows. The compound's stability and storage requirements must be strictly observed to maintain experimental reproducibility (APExBIO).

Biological Rationale

Inwardly rectifying potassium channels (Kir) regulate membrane potential and potassium ion transport in excitable tissues. Kir2.1, encoded by the KCNJ2 gene, is highly expressed in cardiovascular and smooth muscle cells. Dysregulation of Kir2.1 activity contributes to abnormal PASMC proliferation and migration, central to pulmonary vascular remodeling observed in pulmonary hypertension (PH) (Cao et al., 2022). The hallmark of PH is medial pulmonary artery hyperplasia, primarily driven by PASMC dysfunction. Modulation of Kir2.1 has emerged as a target for dissecting mechanisms underlying vascular remodeling and for validating new therapeutic strategies. ML133 HCl, as a selective inhibitor, allows for specific interrogation of Kir2.1 function without confounding off-target effects observed with less selective compounds (Banorl24 article).

Mechanism of Action of ML133 HCl

ML133 HCl acts as a potent, allosteric inhibitor of Kir2.1 potassium channels. At pH 7.4, its IC₅₀ is 1.8 μM; this increases to 290 nM at pH 8.5, illustrating pH-dependent potency (APExBIO). The compound binds to specific sites on Kir2.1, reducing inward potassium current and leading to membrane depolarization. This action attenuates the signaling pathways that drive PASMC proliferation and migration, including the TGF-β1/SMAD2/3 axis and expression of key proliferation markers (OPN, PCNA) (Cao et al., 2022). ML133 HCl does not inhibit Kir1.1 and shows only weak inhibition of Kir4.1 and Kir7.1, highlighting its selectivity profile. The chemical form supplied by APExBIO is the hydrochloride salt of 1-(4-methoxyphenyl)-N-(naphthalen-1-ylmethyl)methanamine (molecular weight 313.82, formula C₁₉H₁₉NO·HCl), which is insoluble in water but soluble in DMSO and ethanol with mild warming and sonication (APExBIO).

Evidence & Benchmarks

• ML133 HCl inhibits Kir2.1 channels with an IC₅₀ of 1.8 μM at pH 7.4 and 290 nM at pH 8.5 (APExBIO).
• ML133 HCl does not inhibit Kir1.1 and only weakly inhibits Kir4.1 and Kir7.1, confirming high selectivity (Cao et al., 2022).
• In vitro, ML133 HCl suppresses proliferation and migration of human PASMCs induced by PDGF-BB, reducing OPN and PCNA expression and inhibiting TGF-β1/SMAD2/3 signaling (Cao et al., 2022).
• ML133 HCl's selectivity and efficacy in PASMC models have been independently validated in cardiovascular disease research (Atrial-Natriuretic-Factor article).
• Solubility is ≥15.7 mg/mL in DMSO and ≥2.52 mg/mL in ethanol with gentle warming; insoluble in water (APExBIO).

This article extends the mechanistic discussion found in this review by providing updated, benchmarked data on ML133 HCl's performance in recent PASMC models. For a comparative overview of ion channel selectivity, see the analysis at Banorl24; this article clarifies the unique solubility and workflow considerations for ML133 HCl. See Atrial-Natriuretic-Factor.com for broader context on cardiovascular ion channel research; here, we focus on translational PASMC applications.

Applications, Limits & Misconceptions

ML133 HCl is used extensively in:

• Cardiovascular ion channel research, especially for dissecting Kir2.1-mediated mechanisms.
• Pulmonary artery smooth muscle cell proliferation and migration studies.
• Disease modeling of pulmonary hypertension and vascular remodeling.
• Pharmacological validation of Kir2.1 as a target in preclinical models (Cao et al., 2022).

Common Pitfalls or Misconceptions

• ML133 HCl is not a pan-Kir channel inhibitor; it is selective for Kir2.1 and does not inhibit Kir1.1 at physiological concentrations (APExBIO).
• It is not effective in models where Kir2.1 is not expressed or is not the primary driver of cellular phenotype.
• ML133 HCl is insoluble in water; improper solvent use can lead to precipitation and experimental failure (APExBIO).
• Long-term storage of ML133 HCl in solution is not recommended due to limited stability; always prepare fresh aliquots for experiments.
• Results in non-cardiovascular systems (e.g., neural, renal) should be interpreted cautiously unless Kir2.1 is confirmed as a functional target.

Workflow Integration & Parameters

ML133 HCl is supplied as a solid. APExBIO recommends storage at -20°C in a desiccated environment (APExBIO). For solution preparation, dissolve in DMSO (≥15.7 mg/mL) or ethanol (≥2.52 mg/mL) with mild warming and ultrasonic treatment. Avoid water as a solvent. For cell-based assays, dilute the stock solution into culture medium to the desired working concentration immediately before use. Do not store working solutions for extended periods. The compound is widely compatible with standard in vitro proliferation, migration, and signaling assays targeting PASMCs. Researchers working in cardiovascular disease models have successfully integrated ML133 HCl into protocols for validating Kir2.1-dependent pathways (Cao et al., 2022).

Conclusion & Outlook

ML133 HCl, available from APExBIO as the B2199 kit (product page), is a validated, highly selective Kir2.1 channel blocker for cardiovascular and pulmonary vascular research. Its well-characterized inhibition profile, favorable solubility, and pH-dependent potency make it a cornerstone tool for dissecting potassium ion transport and PASMC behavior. Ongoing studies continue to expand its applications in translational disease modeling and target validation. When used with attention to its selectivity and handling requirements, ML133 HCl enables robust, reproducible research into Kir2.1-mediated mechanisms in cardiovascular disease.